A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and Challenges
Glen J. Weiss, Winnie S. Liang, Michael J. Demeure et al. · PLoS ONE · 2013
PURPOSE: New anticancer agents that target a single cell surface receptor, up-regulated or amplified gene product, or mutated gene, have met with some success in treating advanced cancers. However, patients' tumors still eventually progress on these therapies. If it were possible to identify a larger number of targetable vulnerabilities in an individual's tumor, multiple targets could be exploited with the use of specific therapeutic agents, thus possibly giving the patient viable therapeutic alternatives. EXPERIMENTAL DESIGN: In this exploratory study, we used next-generation sequencing technologies (NGS) including whole genome sequencing (WGS), and where feasible, whole transcriptome sequencing (WTS) to identify genomic events and associated expression changes in advanced cancer patients. RESULTS: WGS on paired tumor and normal samples from nine advanced cancer patients and WTS on six of these patients' tumors was completed. One patient's treatment was based on targets and pathways identified by NGS and the patient had a short-lived PET/CT response with a significant reduction in his tumor-related pain. To design treatment plans based on information garnered from NGS, several challenges were encountered: NGS reporting delays, communication of results to out-of-state participants and their treating oncologists, and chain of custody handling for fresh biopsy samples for Clinical Laboratory Improvement Amendments (CLIA) target validation. CONCLUSION: While the initial effort was a slower process than anticipated due to a variety of issues, we demonstrate the feasibility of using NGS in advanced cancer patients so that treatments for patients with progressing tumors may be improved.
Cited by 32 works. doi:10.1371/journal.pone.0076438 Open-access PDF
Authors
- Glen J. Weiss
- Winnie S. Liang
- Michael J. Demeure
- Jeffrey Kiefer
- Galen H. Hostetter
- Tyler Izatt
- Shripad A. Sinari
- Alexis Christoforides
- Jessica Aldrich
- Ahmet A. Kurdoglu
- Hollie Benson
- Rebecca A. Reiman
- Angela S. Baker
- Vickie Marsh
- Daniel D. Von Hoff
- John David Carpten
- David Wesley Craig
References
- Database resources of the National Center for Biotechnology Information: update
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- Database resources of the National Center for Biotechnology Information
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002
- Therapeutic response in phase I trials of antineoplastic agents.
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.
- Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
- Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing